At a biological level, obesity is described as a systemic immunometabolic disorder that can promote chronic inflammation, adipokine imbalance and metabolic stress. These processes are linked in the reviewed evidence to signaling pathways including IL-6/STAT3, NF-κB, insulin/IGF-1 and PI3K/AKT/mTOR. Obesity-associated changes may also contribute to lipid metabolic rewiring in malignant cells and to remodeling of stromal and myeloid components in the lymphoma microenvironment.

These mechanisms provide a biological framework connecting adipose-tissue dysfunction with features of lymphoma, but the review does not present them as a single, uniform pathway applicable to every patient or lymphoma subtype. Advances in single-cell and spatial transcriptomics, multi-omics profiling and integrative bioinformatics have refined the analysis of these immunometabolic interactions. The review identifies them as tools for improving biomarker discovery and risk stratification.

Its wider argument is that clinically relevant obesity phenotypes may need to be defined using body composition and metabolic profiling in addition to body mass index, which is an imperfect surrogate for biologically relevant adiposity. Clinical findings for patients with diffuse large B-cell lymphoma are mixed. The review cautions that this pattern may reflect reverse causality, collider bias or limitations inherent to BMI-based analyses, so it should not be interpreted as evidence that obesity itself improves response or survival.

Evidence concerning obesity-associated metabolic alterations, CAR-T-cell kinetics and inflammatory toxicity is also emerging and heterogeneous. The review states that these factors may influence CAR-T-cell behavior, while their impact on therapeutic efficacy remains uncertain. Measurement limits complicate interpretation across the lymphoma literature.

BMI does not adequately distinguish visceral fat accumulation from other aspects of excess adiposity, nor does it capture insulin resistance, inflammatory activation, muscle depletion or the condition identified in the review as sarcopenic obesity. The authors therefore call for research that integrates body-composition assessment, metabolic profiling and multi-omics approaches when evaluating lymphoma risk and outcomes. The review’s main conclusion is not that obesity has one fixed effect on lymphoma, but that its associations vary across biological and clinical contexts.

Progress will depend on distinguishing these contexts rather than treating body mass index as a complete explanation of an individual patient’s metabolic state.

Subject of Research: Obesity-associated immunometabolic effects on lymphoma risk, biology and clinical outcomes

Article Title: Obesity and lymphoma: from pathobiology to clinical outcomes

Article References: Amanda, C., Carmela, D., Francesco, G., Francesca, P., & Stefano, M. (2026). Obesity and lymphoma: from pathobiology to clinical outcomes. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09092-z

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09092-z

Keywords: obesity, lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, immunometabolism, cancer metabolism, body composition, multi-omics, CAR-T cells, chemoimmunotherapy, pathobiology, clinical